| Bioactivity | AZD2716 is a selective sPLA2 (secretory phospholipase A2) inhibitor. AZD2716 significantly reduces the production of pro-inflammatory lipids by inhibiting sPLA2-IIa (IC50 = 10 nM), sPLA2-V (IC50 = 40 nM), and sPLA2-X (IC50 = 400 nM), thereby decreasing macrophage activation and foam cell formation. AZD2716 is promising for studying mechanisms related to atherosclerosis and inflammatory diseases associated with sPLA2[1]. |
| CAS | 1845753-81-2 |
| Formula | C24H23NO3 |
| Molar Mass | 373.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karlsson S, et al. An enantioselective hydrogenation of an alkenoic acid as a key step in the synthesis of AZD2716[J]. Organic Process Research & Development, 2016, 20(2): 262-269. [2]. Giordanetto F, et al. Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease. ACS Med Chem Lett. 2016 Aug 9;7(10):884-889. |